Subscribe
360b-shutterstock-com-2-
360b / Shutterstock.com
6 August 2015Americas

European Commission approves Pfizer’s buyout of Hospira

The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.

More on this story

Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers